SpineGuard, a company listed on Euronext Growth, and specialized deploying its proprietary real time sensing technology DSG® (Dynamic Surgical Guidance) to streamline the placement of implants in the skeleton, announces a new equity financing.

This new financing aims at securing the Company’s cash runway in the context of both the COVID-19 pandemic and the Chapter 11 and French ‘sauvegarde’ plans currently being prepared.

This new financing amounting to 2.4 millions euros has been structured in the form of issuance of pre-paid warrants fully subscribed by Nice & Green, a company specialized in providing corporate services and flexible financing solutions to listed companies.

This issuance of pre-paid warrants in several tranches allows SpineGuard to receive 90% of the amount of each tranche at the subscription and to benefit upfront from almost of the amount of such tranches, the remaining amount being provided at the exercice of the warrants.

Nice & Green has been advised by Solferino Associés (Fouad Bellaaroussi).

SpineGuard has been advised by FLV Associés (Bastien Mathieu).

Read the press release published by SpineGuard

Amoeba Biocide, producer of a biological biocide, capable of eliminating bacterial risk in water and human wounds, and a biocontrol product for plant protection, listed on Euronext Paris, issues a new convertible bonds facility.

This financing of 6.5M€ subscribed by Nice & Green, a company specialized in providing corporate services and flexible financing solutions to listed companies, aims at supporting the activities of Amoeba up to August 2021, especially (i) the R&D activities on the biocontrol application for the prevention of plant diseases such as downy mildew, potato downy mildew, cereal rust and (ii) the applications for authorization of the active substance biocide and the plant protection substance in Europe and United States.

Nice & Green has been advised by Solferino Associés (Fouad Bellaaroussi & Camille Chastagner).

Amoeba Biocide has been advised by Lamy Lexel (Vincent Medail & Aymeric Vuillermet).

For its Series C, Qonto raised €104 million. Tencent and DST Global are joining historical investors Valar Ventures and Alven Capital in this transaction.

Solferino Associés (Bernard-Olivier Becker & Marie Estelle Colin) assisted Qonto on contractual and corporate law aspects, with the assistance of Cazals Manzo Pichot Saint Quentin (Maxence Manzo & Bertrand de Saint-Quentin) on tax aspects.

The Valar and Alven funds were advised by Jones Day, Tencent was advised by Clifford Chance and DST Global was advised by Goodwin.

Rothschild & Co, 123 Investment Managers and SLP entered into an agreement with Cushman & Wakefield, a major global real estate services provider listed on the New York Stock Exchange, relating to the sale of REPONSE, one of the major French design & build services provider.

Rothschild & Co et 123 Investment Managers, who initially invested as Mezzanine instruments, entered the Company’s capital in 2016 in the context a restructuring process and have been involved in the Company together with the Management since then.

This strategic acquisition, which offers complementary services to Cushman & Wakefield in France, is still subject to French Antitrust Authority.

Rothschild & Co et 123 Investment Managers have been advised by Solferino Associés (Fouad BELLAAROUSSI & Camille CHASTAGNER).

SLP has been advised by MBL Associés (Maguelone BEAUMOENT-LORIOT).

Cushman & Wakefield has been advised by DLA Piper.

Vulcain advised the sellers as M&A Advisor (Gauthier BAIJOT & Cyprien BERTHIER).

This capital increase amounting to € 10 millions aimed at partially refinancing two major acquisitions carried out in 2018:

• 100% stake in Infologic-Santé, leading publisher in France in Pathology and Genetics solutions, which equips more than 75% of hospitals and private laboratories with its solutions, for a total of € 6 millions; and
• 100% stake in DL Santé, a medical software publisher mainly positioned in the segment of private medical biology laboratories, for a total of € 10.5 millions.

The success of this capital increase was guaranteed by Dedalus S.p.A, after this capital increase, 81.83% of the capital and 82.01% of the voting rights of Medasys.

Dedalus S.p.A and Medasys were advised by Solferino Associés (Fouad Bellaaroussi, Marie-Estelle Colin and Camille Chastagner).